Harness High-Quality PBPK Modeling To Enhance Preclinical And Clinical Readiness

By Deanna Mudie, Ph.D., Senior Principal Engineer, Lonza Small Molecules, and John DiBella, President, SLP Division, Simulations Plus

Rapid and efficient development of drug candidates sits top of mind for pharmaceutical companies with funding constraints looking to accelerate timelines. Unfortunately, many early drug candidates demonstrate poor oral absorption properties, which can make it challenging to achieve target pharmacokinetic profiles. Without up-front knowledge of absorption risks and mitigation strategies, poor absorption can significantly impact preclinical and clinical study timelines and costs.

However, advancements in physiologically based pharmacokinetic (PBPK) modeling are making it easier than ever to identify and mitigate absorption risks in early drug development. A wide range of approved drugs have utilized PBPK modeling to develop safer, more effective formulations and eliminate unnecessary animal and human studies. Download the full article to learn more about how utilizing PBPK modeling in your early development studies can help you identify drug absorption risks, formulate risk mitigation strategies, and de-risk your preclinical and clinical study outcomes.